Searchable abstracts of presentations at key conferences in endocrinology

ea0081p305 | Calcium and Bone | ECE2022

Reliability of who fracture risk assessment tool (frax) and bone mineral density in predicting fractures in cancer patients under hormone deprivation therapies: a real-world clinical study

Vena Walter , Piccini Sara , Pedersini Rebecca , Carrone Flaminia , Cosentini Deborah , Zucali Paolo , Torrisi Rosalba , Brunetti Alessandro , Pigni Stella , Maroldi Roberto , Balzarini Luca , Lania Andrea Gerardo , Berruti Alfredo , Berruti Gherardo

Background: Skeletal fragility is an important clinical issue in women with early-stage breast cancer and men with non-metastatic prostate cancer under hormonal hormone deprivation therapies (HDTs). Vertebral fractures (VFs) have been reported in a remarkable number of subjects exposed to HDT especially when the diagnosis of fractures is performed by a radiological and morphometric approach. Notably, prediction of fractures in this clinical setting is a challenge and determina...

ea0026oc2.1 | Neuroendocrinology | ECE2011

Etoposide, doxorubicin, cisplatin, and mitotane versus streptozotocin and mitotane in adrenocortical carcinoma: preliminary results from the first international phase III trial: the FIRM-ACT study

Fassnacht Martin , Terzolo Massimo , Allolio Bruno , Baudin Eric , Haak Harm , Berruti Alfredo , Mueller Hans-Helge , Skogseid Britt

Background: No randomized trials have been conducted in adrenocortical carcinoma (ACC) patients. Treatment recommendations for this rare but aggressive disease have been based on data from small phase II trials. We have now performed the first randomized phase III trial, comparing etoposide, doxorubicin, cisplatin, plus mitotane (EDP-M) against streptozotocin plus mitotane (Sz-M).Methods: Three-hundred and four chemotherapy-naive patients with ACC not am...

ea0014p126 | (1) | ECE2007

Clinical and biochemical effects of adjuvant mitotane treatment in patients with adrenocortical cancer (ACC)

Daffara Fulvia , De Francia Silvia , Reimondo Giuseppe , Zaggia Barbara , Sperone Paola , Di Carlo Francesco , Angeli Alberto , Berruti Alfredo , Terzolo Massimo

Objective: Seventeen patients (9 women, 8 men aged 36 years, 22–58) radically resected for ACC were treated with adjuvant mitotane and prospectically followed from 2000 to 2006.Methods: Stage of ACC: was: 1 stage I,; 12 stage II, 4 stage III; Weiss score 6, 3–9; Ki67% 20, 4–67. Eleven patients had functional tumors. Median duration of treatment was 15 months (range:4–84) and 14 patients are currently on mitotane, 2 died, 1 discontinue...

ea0081oc8.1 | Oral Communications 8: Calcium and Bone | ECE2022

Effectiveness of anti-resorptive drugs on risk of vertebral fractures in women receiving aromatase inhibitors: a prospective study in real-life clinical practice

Mazziotti Gherardo , Vena Walter , Pigni Stella , Carrone Flaminia , Pedersini Rebecca , Cosentini Deborah , Torrisi Rosalba , Birtolo Maria Francesca , Maida Giulia , Berruti Alfredo , Lania Andrea

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

ea0026p27 | Adrenal cortex | ECE2011

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

Ardito A , Al Ghuzian A , Fassnacht M , Daffara F , Leboulleux S , Wortmann S , Zaggia B , De Francia S , Volante Marco , Gonzaga Luigi , Berruti Alfredo , Allolio Bruno , Baudin Eric , Terzolo Massimo

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 16–76) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31...

ea0022p424 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

Hermsen Ilse , Fassnacht Martin , Terzolo Massimo , Houterman Saskia , Hartigh Jan den , Leboulleux Sophie , Daffara Fulvia , Allolio Bruno , Berruti Alfredo , Chadarevian Rita , Haak Harm , Baudin Eric

Introduction: O,p’DDD is the drug of choice for patients with adrenocortical carcinoma (ACC). Monitoring o,p’DDD serum level has been proposed as predictor of tumour response. Measurement of o,p’DDD metabolites involved in the active pathway may provide an improved prediction of o,p’DDD activity. The objective of our study was to (1)to confirm the currently used threshold o,p’DDD serum level of 14mg/l for achieving a tumour response and (2)compare the ...

ea0020p188 | Endocrine tumours and neoplasia | ECE2009

Efficacy of repeat surgery in patients with recurrent adrenocortical cancer

Daffara Fulvia , De Francia Silvia , Ardito Arianna , Zaggia Barbara , Fiori Cristian , Angeli Alberto , Scarpa Roberto , Porpiglia Francesco , Perotti Paola , Berruti Alfredo , Terzolo Massimo

The optimal treatment of recurrent adrenocortical cancer (ACC) remains to be established since there are discrepant opinions on the value of repeat surgery. We did a retrospective analysis of the outcome of patients who were referred to our units from 1988 to 2006 for a recurrence of ACC, which occurred 2–83 years after radical removal of the tumor. In that period, the treatment policy of ACC recurrence differed among our units, since oncologists were more accustomed to u...

ea0081oc2.6 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

Puglisi Soraya , Cosentini Deborah , Grisanti Salvatore , Basile Vittoria , Lagana Marta , Ferarri VittorioDomenico , Abate Andrea , Calabrese Anna , Rossini Elisa , Perotti Paola , Saba Laura , Pia Anna , Sigala Sandra , Berruti Alfredo , Terzolo Massimo

Background: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. The aim of this study was to assess the activity of AA to control corti...

ea0049gp231 | Thyroid Cancer | ECE2017

Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study

Mazziotti Gherardo , Panarotto Maria Beatrice , Arvat Emanuela , Chiti Arturo , Cuocolo Alberto , Dottorini Massimo , Elisei Rossella , Filetti Sebastiano , Filice Angelina , Formenti Anna Maria , Pace Leonardo , Pellegrino Teresa , Nodari Marcello , Salvatori Massimo , Tranfaglia Cristina , Versari Annibale , Frara Stefano , Berruti Alfredo , Giustina Andrea , Giubbini Raffaele

Although differentiated thyroid cancer (DTC) has the third highest propensity to spread to the bone after breast and prostate cancer, there is a paucity of data concerning the treatment of bone metastasis (BM) in this setting. The MOSCATI (Metastasi OSsee da Carcinoma TIroideo) was a multicenter, retrospective study investigating the real-life outcome and management of BM in 143 patients (80 F, 63 M; median age 60 years) with DTC involving 10 specialized cente...

ea0070oc1.6 | Adrenal and Cardiovascular Endocrinology | ECE2020

Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study

Elhassan Yasir , Altieri Barbara , Berhane Sarah , Cook Harriet , Bertherat Jerome , Fragoso Maria , Kastelan Darko , Terzolo Massimo , Calabrese Anna , Berruti Alfredo , Cosentini Deborah , Laganà Marta , Loli Paola , Baudin Eric , Haak Harm , Canu Letizia , Haissaguerre Magalie , Kimpel Otilia , Deeks Jon , Arlt Wiebke , Libé Rossella , Fassnacht Martin , Ronchi Cristina

Background: Adrenocortical carcinoma (ACC) has an aggressive but heterogenous behaviour. ENSAT stage and Ki67 proliferation index are used to predict clinical outcome but are limited in distinguishing patients with best outcome. We aimed to validate the prognostic role of clinical and histopathological parameters alone or combined by applying a previously proposed points-based score (mGRAS, Lippert JCEM 2018) to a large multicentre cohort of ACC patients.<p class="abstext"...